CGON vs RMBS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CGON · CG Oncology$79.47 ▼ 2.97%
RMBS · Rambus$66.35 ▼ 12.92%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CGON +82.4%
- RMBS -28.5%
Head to head
| Metric | CGON | RMBS |
|---|---|---|
| Price | $79.47 | $66.35 |
| Change today | ▼ 2.97% | ▼ 12.92% |
| Market cap | $7.10B | $7.11B |
| Return, 3 months | +1.6% | -23.8% |
| Return, year to date | +91.4% | -27.8% |
| Return, 1 year | +87.3% | -24.7% |
| P/E (TTM) | – | 27.4 |
| P/B | 7.2 | 5.0 |
| P/E percentile vs own 5y | 47th | 58th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -3.7% | +22.3% |
| Net profit growth (YoY) | -29.9% | +54.1% |
| Gross margin | -104.8% | 79.1% |
| Operating margin | -4,293.5% | 36.7% |
| Net margin | -3,851.1% | 33.4% |
| Return on equity | -28.3% | 19.6% |
| Analyst target vs. price | +13.3% | +87.4% |
| Analyst buy share | 100% | 50% |
| RSI (14) | 60 | 32 |
| 30-day volatility | 75.2% | 92.5% |
| Max drawdown, 1 year | -27.4% | -61.1% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RMBS is the largest of the group by market value.
- CGON has returned the most over the past year.
- RMBS is growing revenue fastest.
- RMBS keeps the most profit per dollar of sales.
- CGON has been the calmest stock over the last 30 days.